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Abstract: Methotrexate has been used widely in dermatology, oncology and rheumatology fields. However, methotrexate-
induced mucocutaneous lesions may occur in rare cases. In this case presentation, we report two cases of ac-
cidental poisoning with methotrexate. They had accidentally used methotrexate instead of digoxin. This case
report emphasizes that early diagnosis and appropriate management is critical in order to improve outcome.
Keywords: Methotrexate; skin ulcer; toxicity; poisoning; case reports; emergency treatment
© Copyright (2017) Shahid Beheshti University of Medical Sciences
Cite this article as: Bidaki R, Kian M, Owliaey H, Babaei Zarch M, Feysal M. Accidental Chronic Poisoning with Methotrexate; Report of Two
Cases. Emergency. 2017; 5 (1): e67.
1. Introduction
Methotrexate (MTX) is a systemic immunosuppressive agent
that was introduced in the 1950s (1, 2). It is a folate an-
timetabolite that binds to an enzyme named dihydrofolate
reductase, which ultimately leads to inhibition of DNA syn-
thesis (3, 4). MTX is a drug used in treatment of various
malignancies, early ectopic pregnancy or chronic inflamma-
tory diseases such as some types of carcinoma, rheumatoid
arthritis, psoriasis and etc. (5, 6). Accidental poisoning with
MTX is not a common condition and was rarely reported in
the literature (7). Most of our knowledge regarding MTX poi-
soning were derived from serious adverse reactions at thera-
peutic doses or reports about acute oral overdose (8). Unlike
previously reported cases, here we report two cases of acci-
dental chronic poisoning with MTX.
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2. Case report
2.1. Case 1
The patient was an 88-year-old woman. She was admit-
ted to the emergency department with weakness as main
chief complaint. She had dyspnea, gastrointestinal symp-
toms such as nausea and vomiting, abdominal pain, dys-
pepsia, pruritus, epistaxis, and mouth sores from 3 days ago.
The symptoms were progressive. In evaluation of consumed
drugs it was determined that she has been continuously tak-
ing MTX for about 5 months. In search for the cause of taking
MTX and checking the prescriptions, it was revealed that the
drug store had mistakenly given the patient MTX instead of
digoxin. She had used MTX 1.25 mg for 5 consecutive months
and 2.5 mg five days a week in the last month. On admis-
sion, her vital signs were as follows: Blood Pressure = 90/60
mmHg, Pulse Rate = 82/minutes, Respiratory Rate = 12/min-
utes and Temperature = 38.2◦C. On physical examination,
generalized erythema involving back and leg, face edema,
mucositis, stomatitis and difficulty in gait were apparent. Ex-
amination of other organs did not reveal any positive find-
ings. Figure 1 shows her mucocutaneous lesions at presenta-
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Figure 1: Mucocutaneous lesions in case number 1.
tion. Laboratory test results on admission were as follows:
Hemoglobin=9.1 g/dl, WBC=3200/mm3, Platelet counts =
50000/mm3, BUN = 81 mg/dl, creatinine=1.8 mg/dl, AST=18
IU/L, ALT=17 IU/L, PT=14s, PTT=36s, INR=1.14, Bilirubin to-
tal=1.2 mg/dl and Bilirubin Direct=0.3 mg/dl. She was ad-
mitted to intensive care unit (ICU). Platelets, folinic acid (as
MTX antidote), antibiotics and granulocyte colony stimulat-
ing factor (G-CSF) were administered and dermatology cares
were considered for her. Finally, she died due to pulmonary
edema resulting from her underlying cardiac disease 4 days
after admission.
2.2. Case 2
The patient was a 68-year-old woman, who was referred to
the emergency department because of oral ulcer, limb pares-
thesia and difficulty initiating movement from one week ago.
Muscular force was reduced gradually. The patient didn’t
have any history of trauma. The patient had accidentally
used one MTX tablet each day, instead of Digoxin, since
one month ago (due to a mistake in the drug store, she was
given MTX instead of digoxin). In the past medical his-
tory, the patient had a history of diabetes mellitus, hyperten-
sion, heart failure and hyperlipidemia. Other drugs used by
the patient included losartan, aspirin, carvedilol, L-carnitine
and triamterene-H. On admission, she was alert and her vi-
tal signs were as follows: Blood Pressure = 110/70 mmHg,
Pulse Rate = 74/minute, Respiratory Rate =16/minute and
Temperature = 36.8◦C. On physical examination, level of
consciousness was normal. There was no evidence of res-
piratory distress. Neurological examinations revealed nor-
mal cerebellar tests. Upper limb muscular force was nor-
mal and lower limb force was 4/5 in proximal and 3/5 in
distal. Hemorrhagic ulcers were seen in palate and lips.
Figure 2 shows her mucocutaneous lesions at presentation.
Laboratory tests were as follows: Hemoglobin=11.2 g/dl,
WBC=10.9/mm3, Platelet counts = 20000/mm3, Natrium =
140 mEq/l, Potassium = 3.5 mEq/l, urea=36 mg/dl, creati-
nine=0.85 mg/dl, PT=13 s, PTT=27 s, INR=1.3, ALT=43 IU/L,
AST=34 IU/L, ALP=200 IU/L. Magnetic resonance imaging
(MRI) and also electromyogram/nerve conduction velocity
(EMG/NCV) tests were normal. Echocardiography revealed
ejection fraction (EF) of 20%. With diagnosis of MTX poison-
ing, the patient underwent treatment with folinic acid for 10
days. The patient was discharged with good general condi-
tion and improvement of weakness and lower limb paresthe-
sia 5 days later.
3. Discussion
MTX toxicity is characterized by nausea, vomiting, diarrhea,
myelosuppression, pancytopenia, liver dysfunction, acute
renal failure (ARF), pulmonary symptoms, mucositis, stom-
atitis, ulceration/erosion of the gastrointestinal system and
cutaneous ulcerations (9-11). Although methotrexate toxic-
ity can cause kidney injury and change the renal function,
sometimes renal dysfunction like an acute renal failure can
also induce methotrexate toxicity (4, 12-14). However, cuta-
neous ulceration may be considered as an early clinical sign
of imminent systemic toxicity and patients may only present
with isolated cutaneous lesions (15-17). The side effects of
MTX may occur through dose dependent or idiosyncratic
mechanisms. Interestingly, dose dependent mechanism oc-
curs in bone marrow cells, epidermal cells and epithelial gas-
trointestinal system. Some factors such as drug interactions
and incorrect administration of drugs are triggers for ap-
pearance of side effects (9). Simultaneous use of MTX with
drugs interacting with it such as proton-pump inhibitors,
trimethoprim/sulfamethoxazole, doxycycline, non-steroidal
anti-inflammatory drugs (NSAIDs), and salicylates that de-
crease protein binding or reduce renal clearance, as well as
excessive alcohol consumption could play an important role
in this regard (18). Elevation of serum aminotransferase lev-
els, elevation in serum uric acid, leukopenia, thrombocy-
topenia, and anemia may be noticed in laboratory tests of
MTX poisoned patients (19). Measurement of methotrex-
ate concentration via radioimmunoassay in plasma, serum,
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Figure 2: Mucocutaneous lesions in case number 2.
or urine samples could lead to definite diagnosis (19). Di-
agnostic biopsy from ulceration sites is rarely required, but
helpful (2). Withdrawal of MTX and administration of in-
travenous folinic acid (leucovorin) as early as possible after
exposure is the most effective initial treatment that should
not be delayed for any reason (2, 19). Treat persistent nausea
and vomiting with several antiemetic agents such as meto-
clopramide, ondansetron, promethazine, haloperidol, ben-
zodiazepines, or even corticosteroids. Intravenous fluids and
urine alkalization via bicarbonate infusion are highly ad-
vised. Administration of colony stimulating factors is nec-
essary if severe neutropenia exists. Transfusion of platelets
and/or packed red cells may be needed in patients with se-
vere thrombocytopenia, anemia, or hemorrhage. The patient
should be closely monitored for signs of bleeding, clinical ev-
idence of infection, abnormalities in serum electrolytes, re-
nal failure and hepatic function. A chest radiograph should
be obtained in patients with respiratory symptoms and skin-
directed therapy must to be applied (19). In patients with
impaired renal function who develop toxicity and in cases
of acute overdose, glucarpidase has been used to rapidly ca-
tabolize MTX to an inactive metabolite, aiding its clearance
(2, 19, 20). Although MTX toxicity can be a fatal poisoning,
proper management, early diagnosis and follow-up of the pa-
tients in emergency department as well as in ICU can resolve
the complications and save the patients’ lives. It seems that
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